Saccharomyces boulardii improves H. pylori eradication rate Original paper
In this meta-analysis of 19 randomized controlled trials in 5,036 total participants with Helicobacter pylori infection, adding the probiotic Saccharomyces boulardii to standard care improved the chances of Helicobacter pylori eradication by 11%, compared with standard care alone.
This Study Summary was published on April 18, 2025.
The study
The trials examined adults in 15 studies and children in 4 studies. The participants were given standard care (a combination of 3 or 4 medications), along with Saccharomyces boulardii, a placebo, or nothing for 10 to 28 days.
The primary outcomes were Helicobacter pylori eradication rates and total adverse events. The secondary outcomes were bloating, constipation, diarrhea, and nausea.
Adding Saccharomyces boulardii to standard care reduced the risk of total adverse events by 51% (9 studies) and reduced bloating, constipation, diarrhea, and nausea by 51% to 64% (6–16 studies).
In subgroup analyses, Saccharomyces boulardii reduced Helicobacter pylori eradication rates in children by 14% and in adults by 9%.
If you do not have an account, please click here to create a free account.
If you want to stay on top of the latest research, .
The results
Get free weekly updates on what’s new at Examine.
This Study Summary was published on April 18, 2025.